Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

BACKGROUND: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additio...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Rubio, Eduardo, Gómez-España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Reboredo, Margarita, Manzano, José Luis, Rivera, Fernando, Safont, MªJosé, Montagut, Clara, González, Encarnación, Benavides, Manuel, Marcuello, Eugenio, Cervantes, Andrés, Martínez de Prado, Purificación, Fernández-Martos, Carlos, Arrivi, Antonio, Bando, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470549/
https://www.ncbi.nlm.nih.gov/pubmed/23174912
http://dx.doi.org/10.1371/journal.pone.0047345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470549/
https://www.ncbi.nlm.nih.gov/pubmed/23174912
http://dx.doi.org/10.1371/journal.pone.0047345

Ejemplares similares